# Enzyme Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/enzyme

- Industry: Software
- Headquarters: San Francisco, US
- Website: www.enzyme.com
- Total disclosed funding: $1.9M
- Latest round: Seed (Oct 10, 2017)
- Investors on record: 5

## About

Enzyme Corporation is a provider of an Electronic Quality Management System (eQMS) focused on enhancing quality management processes within the life sciences sector, including medical devices and biopharma companies.Founded in 2015, Enzyme Corporation specializes in developing a comprehensive Electronic Quality Management System (eQMS). Headquartered in San Francisco, US, the company has undergone significant growth since its establishment, raising USD 1.9 mn in a Seed funding round in October 2017. The funding was backed by investors such as Data Collective, Hack VC, Refactor Capital, Rock Health, and Soma Capital Management. The firm has completed a total of 2 deals, indicating robust interest and investment in its offerings. The company was co-founded by Jacob Graham and Jared Seehafer, who previously founded other companies in the tech space. Jared Seehafer currently serves as CEO, guiding the firm towards its growth objectives.Enzyme offers a comprehensive Electronic Quality Management System (eQMS) tailored specifically for the life sciences sector, including medical device, digital health, and biopharma companies. The core product is designed to streamline and enhance quality management processes, covering the entire product lifecycle from premarket to postmarket, making it suitable for organizations ranging from startups to large enterprises. Key functionalities include document control, change control, training management, risk management, and compliance solutions, all developed with input from quality and regulatory professionals. Enzyme's eQMS is characterized by its flexibility and scalability, allowing users to integrate it with existing tools and import data easily, thus fostering a more efficient workflow. The company serves a global customer base, particularly focusing on markets in North America, Europe, and Asia.Enzyme's business model centers around subscription-based transactions, where clients pay for access to its eQMS platform and associated functionalities. The revenue is generated primarily through annual subscriptions that provide continuous access to the software, ensuring updates and customer support throughout the contract term. The firm also offers consulting services to optimize quality management practices, further enhancing customer engagement and satisfaction. Specific pricing details for the subscription plans or consulting services are not publicly disclosed, but the model is structured to cater to both small businesses and larger enterprises, reflecting the diverse needs of its client base.Enzyme Corporation plans to utilize the recent funding of USD 1.9 mn from the October 2017 Seed round to enhance its product offerings and expand geographic reach. The company aims to introduce new features within its eQMS platform, designed to be launched by the end of 2023. Additionally, Enzyme is targeting expansion into the Asian market, specifically South Korea and Japan, with plans to establish a presence there by 2024. The funding will support these initiatives, helping to facilitate product development and market entry.

## Funding rounds

- Seed, Oct 10, 2017, $1.9M — Rock Health, DCVC, Soma Capital Management, Refactor Capital, Hack VC

## Investors

- Rock Health (https://capitalatlas.ai/funds/rock-health) — Seed
- DCVC (https://capitalatlas.ai/funds/dcvc) — Seed
- Soma Capital Management (https://capitalatlas.ai/funds/soma-capital-management) — Seed
- Refactor Capital (https://capitalatlas.ai/funds/refactor-capital) — Seed
- Hack VC (https://capitalatlas.ai/funds/hack-vc) — Seed